Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kamada (KMDA) Current Deferred Revenue (2016 - 2026)

Kamada has reported Current Deferred Revenue over the past 10 years, most recently at $67000.0 for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 67.32% year-over-year to $67000.0; the TTM value through Mar 2026 reached $67000.0, down 67.32%, while the annual FY2024 figure was $171000.0, 15.54% up from the prior year.
  • Current Deferred Revenue was $67000.0 for Q1 2026 at Kamada, down from $205000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $205000.0 in Q1 2025 and bottomed at $35000.0 in Q4 2022.
  • The 5-year median for Current Deferred Revenue is $148000.0 (2023), against an average of $125200.0.
  • Year-over-year, Current Deferred Revenue skyrocketed 322.86% in 2023 and then tumbled 67.32% in 2026.
  • Over 5 years, Current Deferred Revenue stood at $35000.0 in 2022, then skyrocketed by 322.86% to $148000.0 in 2023, then rose by 15.54% to $171000.0 in 2024, then grew by 19.88% to $205000.0 in 2025, then tumbled by 67.32% to $67000.0 in 2026.
  • The last three reported values for Current Deferred Revenue were $67000.0 (Q1 2026), $205000.0 (Q1 2025), and $171000.0 (Q4 2024) per Business Quant data.